Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison

  • K. Kumagai
  • K. Harigane
  • Y. Kusayama
  • T. Tezuka
  • H. Choe
  • Y. Inaba
  • T. Saito
Original Article
  • 34 Downloads

Abstract

Summary

A head-to-head comparison of once-monthly oral bisphosphonates minodronate (MIN) and risedronate (RIS) in patients with rheumatoid arthritis (RA) demonstrated that MIN has the same effect as RIS on increase in bone mineral density (BMD) and a stronger effect on inhibition of bone resorption than RIS, suggesting that MIN is a promising treatment option for osteoporosis patients with RA.

Introduction

To evaluate the effect of once-monthly oral MIN in patients with RA, a prospective, randomized, open-label, head-to-head comparison with once-monthly oral RIS was conducted.

Methods

A total of 83 patients with RA were randomly assigned to either once-monthly oral MIN 50 mg (n = 42) or once-monthly oral RIS 75 mg (n = 41). Serial BMD and bone turnover markers were measured and compared between the treatment groups.

Results

BMD (lumbar spine, total hip, femoral neck) increased significantly after 12 months of treatment with MIN (3.8, 2.0, and 2.2%, respectively, P < 0.05) and RIS (3.6, 1.9, and 1.9%, respectively, P < 0.05). There were no significant differences between the treatment groups. Percent changes of bone turnover markers from baseline to 12 months in the MIN group were significantly greater than those in the RIS group (TRACP-5b: − 36.3 vs − 19.3%, P < 0.05; NTX: − 27.1 vs − 17.3%, P < 0.05; BAP: −30.2 vs −19.4%, P < 0.05).

Conclusions

The present study of RA patients demonstrated that MIN has the same effect as RIS on increase in BMD and a stronger effect on inhibition of bone resorption than RIS. The results suggest that MIN is a promising treatment option for osteoporosis patients with RA.

Keywords

Bone mineral density Bone turnover markers Minodronate Once-monthly oral bisphosphonate Osteoporosis Rheumatoid arthritis Risedronate 

Notes

Compliance with ethical standards

The study protocol and publication were approved by the Institutional Review Board at Yokohama City University (no. B120510026). This study was conducted in accordance with the Declaration of Helsinki and written informed consent was obtained from all subjects.

Conflicts of interest

None.

References

  1. 1.
    Deal C (2012) Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep 14:231–237CrossRefPubMedGoogle Scholar
  2. 2.
    Roux C (2011) Osteoporosis in inflammatory joint diseases. Osteoporos Int 22:421–433CrossRefPubMedGoogle Scholar
  3. 3.
    Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43:522–530CrossRefPubMedGoogle Scholar
  4. 4.
    Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 43:2776–2784CrossRefPubMedGoogle Scholar
  5. 5.
    van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112CrossRefPubMedGoogle Scholar
  6. 6.
    Zerbini CA, Clark P, Mendez-Sanchez L, Pereira RM, Messina OD, Una CR, Adachi JD, Lems WF, Cooper C, Lane NE (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429–446CrossRefPubMedGoogle Scholar
  7. 7.
    Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y, Taniguchi A, Yamanaka H, Momohara S (2015) Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int 26:961–968CrossRefPubMedGoogle Scholar
  8. 8.
    Hoes JN, Bultink IE, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16:559–571CrossRefPubMedGoogle Scholar
  9. 9.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084CrossRefPubMedGoogle Scholar
  10. 10.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437CrossRefPubMedGoogle Scholar
  11. 11.
    Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2013) Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial. J Bone Miner Metab 31:544–550CrossRefPubMedGoogle Scholar
  12. 12.
    Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7:3–20CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMedGoogle Scholar
  14. 14.
    Kamimura M, Nakamura Y, Ikegami S, Komatsu M, Uchiyama S, Kato H (2016) Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate. Osteoporos Sarcopenia 2:170–174CrossRefGoogle Scholar
  15. 15.
    Jacobs JWG, de Nijs RNJ, Lems WF, Bijlsma JWJ (2000) Bone metabolism in rheumatoid arthritis. Clin Exp Rheumatol 18:S5–S11Google Scholar
  16. 16.
    Breuil V, Euller-Ziegler L (2006) Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 73:349–354CrossRefPubMedGoogle Scholar
  17. 17.
    Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 39:396–402CrossRefPubMedGoogle Scholar
  18. 18.
    Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z (2013) Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. PLoS One 8:e80890CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, Yoshikawa H (2016) Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporos Int 27:351–359CrossRefPubMedGoogle Scholar
  20. 20.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMedGoogle Scholar
  21. 21.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33CrossRefPubMedGoogle Scholar
  22. 22.
    Fleisch H (2001) Bisphosphonates: mechanisms of action. Expert Opin Ther Pat 11:1371–1381CrossRefGoogle Scholar
  23. 23.
    Yamamoto K, Yoshino S, Shue G, Nagashima M (2006) Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. Rheumatol Int 26:627–632CrossRefPubMedGoogle Scholar
  24. 24.
    Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K (2008) Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol 35:407–413PubMedGoogle Scholar
  25. 25.
    Ogura Y, Gonsho A, Cyong JC, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:111–119CrossRefPubMedGoogle Scholar
  26. 26.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy Risedronate Ther (VERT) Study Group Osteoporos Int 11:83–91Google Scholar
  27. 27.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971–979CrossRefPubMedGoogle Scholar
  28. 28.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone 59:44–52CrossRefPubMedGoogle Scholar
  29. 29.
    Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • K. Kumagai
    • 1
  • K. Harigane
    • 1
  • Y. Kusayama
    • 1
  • T. Tezuka
    • 1
  • H. Choe
    • 1
  • Y. Inaba
    • 1
  • T. Saito
    • 1
  1. 1.Department of Orthopaedic Surgery, Graduate School of MedicineYokohama City UniversityYokohamaJapan

Personalised recommendations